The revolution of Nutraceuticals through FM-LipoMatrix® technology.

All products of the Norm Line are made with the finest raw materials, which undergo multiple microbiological tests, both in vivo and in vitro, to ensure safety and stability. These tests also confirm the total absence of pesticides, radioactive residues, and chemical contaminants. Production takes place in clean rooms with constantly filtered air to prevent contamination, while temperature and humidity are carefully monitored to guarantee impeccable quality.

The production process follows the strictest GMP (Good Manufacturing Practices) standards for food supplements, as established by the World Health Organization (WHO).

The Norm Line is the result of a truly revolutionary technology, patented and defined as FM-LipoMatrix®.
It is a blend of vegetable oils complexed with specific components, endowed with its own biological activity, capable of enhancing the effectiveness of lipophilic substances in nutraceutical (and pharmaceutical) formulations.

But that’s not all — FM-LipoMatrix® also allows for:
– greater water solubility of fat-soluble substances and improved stability of active components;
– optimized intestinal absorption and increased bioavailability of ingredients, from 50% up to 300%, thanks to an enhanced delivery system;
– a drastic reduction in side effects caused by high dosages.

All active ingredients are initially subjected to the fluidization process: a bed of particles in the product container is transformed into a fluid-like state by an upward flow of liquid or gas. Once the bed is fully fluidized, the granulation liquid is then added — the FM-LipoMatrix® technology.

A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging

Vera Morsanuto *, Rebecca Galla, Claudio Molinari † and Francesca Uberti *,† Laboratory of Physiology, Department of Translational Medicine, University of Piemonte Orientale, Italy
8 May 2020; Accepted: 9 July 2020; Published: 17 July 2020

Palmitoylethanolamide, or PEA, is a long-chain molecule of carbon atoms that combines with palmitic acid and an ethanolamine group.

It is a molecule with highly interesting active properties in cases of chronic or acute pain and inflammation: rather than binding directly to endocannabinoid receptors, it acts as a mediator, participating in the biological response of endogenous cannabinoids and preventing their degradation, thereby prolonging their action against pain.

It is no coincidence that Professor Rita Levi Montalcini was among the most eminent scientific voices in our country to highlight the therapeutic value of the PEA molecule:“Palmitoylethanolamide is orally active in reducing tissue inflammation and mast cell degranulation in vivo, decreasing the hyperalgesia that accompanies peripheral nerve compression.”*.
PEA demonstrates significant anti-inflammatory, analgesic, immunomodulatory, and neuroprotective effects, enabling the restoration of glutamatergic transmission homeostasis. Furthermore, PEA’s ability to modulate protective responses during inflammation derives from its role within the homeostatic system that controls inflammation, counteracting the release of newly synthesized inflammatory mediators by activated mast cells.

Numerous studies and ongoing research highlight the potential of this molecule in the anti-inflammatory and analgesic treatment of clinical conditions with different etiologies. Without side effects.**

The only drawback, within an otherwise exceptional profile, is its low bioavailability.
This is where the FM-LipoMatrix® factor comes into play — and where products such as Artonorm and Peanorm were born.

* Levi-Montalcini R; Trends Neurosci. 1996 Nov;19(11):514-20. Review

** Review: The Basal Pharmacology of Palmitoylethanolamide
Linda Rankin † and Christopher J. Fowler * Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden;
Published: 26 October 2020

The innovation of Hyaluronic Acid for joint well-being

Hyaluronic Acid plays a fundamental role in the health and stability of the joint environment: the positive response to the stresses required by movement and the natural variations in load largely depend on its presence in terms of both quantity and quality. In individuals with osteoarthritis, for example, the molecular weight and concentration of Hyaluronic Acid are reduced, leading to cartilage degeneration.

To address this issue, LeadingMed has developed the Reviscon Line and the Vis Line, harnessing the unique viscous and elastic properties of a truly innovative Hyaluronic Acid, the result of extensive scientific research and sector studies.

– The REVISCON LINE offers an infiltrative therapy with high molecular weight, based on a new-generation, highly biocompatible Hyaluronic Acid.

Reviscon is a high molecular weight, highly purified Sodium Hyaluronate, dissolved in physiological solution.
All synovial joints naturally contain viscoelastic Sodium Hyaluronate, especially those that bear weight. In patients with osteoarthritis, for example, the viscoelasticity of synovial fluid is significantly reduced: this causes mechanical stress on the joint, leading to cartilage breakdown, limited mobility, and considerable pain.

Thanks to its product range, the Reviscon Line relieves pain while contributing to the improvement of overall mobility: in fact, the complex viscosity typical of Hyaluronic Acid provides both viscous and elastic properties that are essential for joint well-being.
The excellent rheological profile of the Reviscon Line ensures optimal resting viscosity (up to 5 times higher than many comparable products on the market), and therefore an equally optimal reduction of pain thanks to superior dynamic elasticity when stress is high.

– Reviscon 20 mg in 2 ml: 3–5 infiltrations for gradual therapy;
– Reviscon Mono 48 mg in 2.4 ml: single infiltration, high performance;
– Reviscon Plus 32 mg in 2 ml: high efficacy in 2–3 infiltrations.

The VIS LINE offers an infiltrative therapy based on Hyaluronic Acid, specifically designed to reduce symptoms and inflammatory conditions while increasing lubrication and visco-induction within the joints.

RenehaVis (Mix LMW-HMW a doppia camera) – 1 to 3 infiltrations per week
RenehaVis consists of a sterile, pre-filled, ready-to-use dual-chamber glass syringe containing:

– Chamber 1: Low Molecular Weight (LMW) Sodium Hyaluronate – 0.7 ml sterile Sodium Hyaluronate at 2.2%, Molecular Weight 1 × 10⁶ Da.
– Chamber 2: High Molecular Weight (HMW) Sodium Hyaluronate – 0.7 ml sterile Sodium Hyaluronate at 1.0%, Molecular Weight 2 × 10⁶ Da.

RenehaVis is particularly effective in reducing pain and stiffness of the knee joint in patients suffering from synovial joint degeneration.

The high degree of reliability of RenehaVis is due to its physicochemical properties: the LMW and HMW Sodium Hyaluronate contained in RenehaVis is a biopolymer composed of disaccharide units of N-acetylglucosamine and glucuronic acid, obtained through the biosynthesis of Streptococcus equi. It is identical to the Sodium Hyaluronate naturally found in synovial joints, which, however, may have been altered by degenerative or traumatic changes within the synovial joint.

RenehaVis supplements the synovial Sodium Hyaluronate that has undergone alterations in molecular weight and concentration.

TendoVis (soft tissue adapted biocompatible Hyaluronic Acid) – 2 infiltrations (one per week)
TendoVis is indicated for periarticular infiltrations in cases of damaged or compromised tendons and ligaments.

– modulates inflammation
– reduces pain
– protects and supports the damaged area
– reduces the risk of recurrence
– shortens recovery times
– facilitates proper tendon realignment, leading to functional recovery.

TendoVis is a sterile glass syringe containing Sodium Hyaluronate with pH and osmolarity biocompatible with soft tissues. It is therefore suitable for periarticular injection, specifically in the soft tissues surrounding tendons and ligaments.

TendoVis is indicated for patients with rotator cuff tendinopathy, epicondylitis, and ankle sprains. Thanks to a sophisticated patented manufacturing process (STABHA patent – Soft Tissue Adapted Biocompatible Hyaluronic Acid), it ensures prolonged retention time and prevents degradative reactions by the body (thanks to the absence of endotoxin and nucleic acids).

*The I.D.E.H.A. Study Intra-articular Double Molecular Weight Efficacy of Hyaluronic Acid

Authors: Dr. Romeo Gatti, Xuming Shen – IDEHA Group
Patients: 1,214 patients in Italy (multicenter study involving more than 50 physicians) PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24416477
SAFETY AND EFFECTIVENESS IN PAIN REDUCTION

Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
Authors: Robert J. Petrella, Joseph Decaria, Michael Petrella
PubMed: http://www.pagepress.org/journals/index.php/rr/article/view/rr.2011.e4/2729

EULAR ROME 2010

LONG-TERM EFFECTIVENESS (12–24 MONTHS) AND GREATER EFFICACY COMPARED TO CONVENTIONAL THERAPIES
Efficacy of DualVis (Renehavis) for Knee Osteoarthritis in Indonesia
Authors: Prof. Handono Kalim, Dr. Arif Sumardjono, Dr. Nyimas Fatimah.